Last update June 7, 2022
Incompatible
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Teriflunomide in other languages or writings:
Main tradenames from several countries containing Teriflunomide in its composition:
Variable | Value | Unit |
---|---|---|
Molecular weight | 270 | daltons |
Protein Binding | 99 | % |
VD | 0.16 | l/Kg |
Tmax | 1 - 4 | hours |
T½ | 432 - 456 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by IHAN of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is the main active metabolite of leflunomide. It inhibits the synthesis of pyrimidine and has immunomodulatory, anti-inflammatory and immunosuppressive properties. Indicated in the treatment of multiple sclerosis. Oral administration once a day.
Since the last update we have not found published data on its excretion in breastmilk.
Its high binding to plasma proteins makes its transfer to milk in significant concentrations unlikely.
Its slow elimination (half-life of 18-19 days) and its potentially serious side effects means it is recommended that, until there is more published information about this drug in relation to breastfeeding, safer alternatives are used (Sammaritano 2020, Alroughani 2016, Almas 2016, Cree 2013), especially during the neonatal period and in case of prematurity.
See below the information of this related product: